Loading...

Midatech Pharma

DB:5MPB
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
5MPB
DB
£33M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The last earnings update was 205 days ago. More info.


Add to Portfolio Compare Print
  • Midatech Pharma has significant price volatility in the past 3 months.
5MPB Share Price and Events
7 Day Returns
-7.5%
DB:5MPB
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-75.3%
DB:5MPB
-10.2%
DE Biotechs
-6%
DE Market
5MPB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Midatech Pharma (5MPB) -7.5% 51% 80.5% -75.3% - -
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • 5MPB underperformed the Biotechs industry which returned -10.2% over the past year.
  • 5MPB underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
5MPB
Industry
5yr Volatility vs Market
Related Companies

5MPB Value

 Is Midatech Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Midatech Pharma. This is due to cash flow or dividend data being unavailable. The share price is €0.074.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Midatech Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Midatech Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:5MPB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in GBP £-0.27
AIM:MTPH Share Price ** AIM (2019-04-18) in GBP £0.08
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Midatech Pharma.

DB:5MPB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:MTPH Share Price ÷ EPS (both in GBP)

= 0.08 ÷ -0.27

-0.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Midatech Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Midatech Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Midatech Pharma's expected growth come at a high price?
Raw Data
DB:5MPB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Midatech Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Midatech Pharma's assets?
Raw Data
DB:5MPB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in GBP £0.38
AIM:MTPH Share Price * AIM (2019-04-18) in GBP £0.08
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:5MPB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:MTPH Share Price ÷ Book Value per Share (both in GBP)

= 0.08 ÷ 0.38

0.21x

* Primary Listing of Midatech Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Midatech Pharma is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Midatech Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Midatech Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

5MPB Future Performance

 How is Midatech Pharma expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
42.3%
Expected annual growth in earnings per share.
Earnings growth vs Low Risk Savings
Is Midatech Pharma expected to grow at an attractive rate?
  • Midatech Pharma's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Midatech Pharma's earnings growth is expected to exceed the Germany market average.
  • Midatech Pharma's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:5MPB Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:5MPB Future Earnings per Share Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 42.3%
DB:5MPB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts -55.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:5MPB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:5MPB Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 1 2
2019-12-31 1 2
2018-12-31 1 2
DB:5MPB Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-06-30 8 -11 -16
2018-03-31 8 -12 -16
2017-12-31 8 -13 -16
2017-09-30 5 -14 -16
2017-06-30 4 -15 -18
2017-03-31 6 -14 -19
2016-12-31 7 -13 -20
2016-09-30 5 -14 -17
2016-06-30 4 -15 -13
2016-03-31 3 -14 -12
2015-12-31 1 -12 -10
2015-09-30 1 -11 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Midatech Pharma's earnings are expected to grow significantly at over 20% yearly.
  • Midatech Pharma's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:5MPB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Midatech Pharma Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5MPB Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -0.09 -0.09 -0.09 1.00
2019-12-31 -0.15 -0.15 -0.15 1.00
2018-12-31 -0.28 -0.28 -0.28 1.00
DB:5MPB Past Financials Data
Date (Data in GBP Millions) EPS *
2018-06-30 -0.27
2018-03-31 -0.29
2017-12-31 -0.31
2017-09-30 -0.33
2017-06-30 -0.41
2017-03-31 -0.48
2016-12-31 -0.56
2016-09-30 -0.50
2016-06-30 -0.43
2016-03-31 -0.40
2015-12-31 -0.36
2015-09-30 -0.44

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Midatech Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Midatech Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Midatech Pharma has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

5MPB Past Performance

  How has Midatech Pharma performed over the past 5 years?

  • Midatech Pharma's last earnings update was 205 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Midatech Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Midatech Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Midatech Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Midatech Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Midatech Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Midatech Pharma Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5MPB Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 7.67 -15.65 11.85 10.19
2018-03-31 7.64 -15.86 12.21 10.19
2017-12-31 7.60 -16.06 12.57 10.19
2017-09-30 4.54 -15.53 6.99 6.91
2017-06-30 4.45 -17.99 9.51 5.75
2017-03-31 5.68 -19.08 13.57 6.77
2016-12-31 6.92 -20.16 17.63 7.80
2016-09-30 5.46 -16.79 12.41 9.76
2016-06-30 4.00 -13.41 12.77 6.15
2016-03-31 2.69 -11.75 9.12 6.03
2015-12-31 1.38 -10.10 2.69 8.71
2015-09-30 0.91 -10.38 5.59 5.06
2015-06-30 0.45 -11.18 6.57 4.20
2015-03-31 0.30 -10.13 5.62 3.92
2014-12-31 0.16 -8.82 4.23 3.64
2014-09-30 0.16 -6.94 3.52 3.32
2014-06-30 0.17 -4.79 2.38 3.00
2014-03-31 0.16 -4.44 2.09 2.92
2013-12-31 0.15 -4.08 1.81 2.84
2012-12-31 -3.99 2.36 1.65

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Midatech Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Midatech Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Midatech Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Midatech Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Midatech Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

5MPB Health

 How is Midatech Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Midatech Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Midatech Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Midatech Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Midatech Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Midatech Pharma Company Filings, last reported 9 months ago.

DB:5MPB Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 23.37 6.68 4.12
2018-03-31 23.37 6.68 4.12
2017-12-31 34.68 6.55 13.20
2017-09-30 34.68 6.55 13.20
2017-06-30 36.81 1.78 6.19
2017-03-31 36.81 1.78 6.19
2016-12-31 45.72 2.16 17.61
2016-09-30 45.72 2.16 17.61
2016-06-30 40.73 1.80 7.23
2016-03-31 40.73 1.80 7.23
2015-12-31 46.89 1.95 16.18
2015-09-30 46.89 1.95 16.18
2015-06-30 37.13 1.69 24.34
2015-03-31 37.13 1.69 24.34
2014-12-31 41.99 1.98 30.33
2014-09-30 41.99 1.98 30.33
2014-06-30 -0.57 3.55 1.87
2014-03-31 -0.57 3.55 1.87
2013-12-31 0.76 3.37 2.39
2012-12-31 -5.09 5.45 0.13
  • Midatech Pharma's level of debt (28.6%) compared to net worth is satisfactory (less than 40%).
  • Midatech Pharma had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Midatech Pharma has less than a year of cash runway based on current free cash flow.
  • Midatech Pharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.9% each year.
X
Financial health checks
We assess Midatech Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Midatech Pharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

5MPB Dividends

 What is Midatech Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Midatech Pharma dividends. Estimated to be 0% next year.
If you bought €2,000 of Midatech Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Midatech Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Midatech Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:5MPB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:5MPB Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Midatech Pharma has not reported any payouts.
  • Unable to verify if Midatech Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Midatech Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Midatech Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Midatech Pharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Midatech Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Midatech Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Midatech Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

5MPB Management

 What is the CEO of Midatech Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Craig Cook
AGE 51
TENURE AS CEO 0.8 years
CEO Bio

Dr. Craig Richard Cook, MBBCH, BSc (Hons), DA, MD, MBA has been Chief Executive Officer and Director of Midatech Pharma Plc since June 1, 2018 and its Chief Operating Officer since January 1, 2014. He was Chief Medical Officer at Midatech Pharma Plc since January 1, 2014. He serves as a Director of 2X1Y Ltd., CareHealth Sarl, SedateUK Ltd, Shawlmist Limited., SpaceCode SA., Swisscare Health Limited., and Winstead Assets Ltd. He served as a Director of Sedation Solutions Limited. Dr. Cook was Head of Research & Development at Midatech Pharma Plc. Dr. Cook joined Midatech in 2014 after leading and concluding the Ippon Capital investment round. He is lead adviser for Ippon Capital SA's life sciences practice. Hehas more than 15 years of international experience in the pharma, biomedical and high technology sectors including roles across a range of therapeutic areas, such as neurology, inflammatory, immunology and endocrine, covering both drug development and medical affairs. He has established and led several healthcare initiatives including SpaceCode Healthcare Technologies, Sedation Solutions and SwissCare Health care provider. Dr. Cook held senior positions at Serono Biotech, Novartis Pharma, Eli Lilly and Johnson & Johnson. He is a qualified physician. Dr. Cook has a B.Sc. in Pharmacology, Diploma in Anaesthesiology and M.B.A. from the London Business School.

CEO Compensation
  • Insufficient data for Craig to compare compensation growth.
  • Insufficient data for Craig to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Midatech Pharma management team in years:

2.2
Average Tenure
51
Average Age
  • The tenure for the Midatech Pharma management team is about average.
Management Team

Nick Robbins-Cherry

TITLE
CFO, Company Secretary & Director
COMPENSATION
£188K
AGE
49
TENURE
5.2 yrs

Craig Cook

TITLE
CEO, COO & Director
AGE
51
TENURE
0.8 yrs

Rob Rainey

TITLE
Head of Corporate Development

Tim Sparey

TITLE
Chief Business Officer

Justin Barry

TITLE
Head of Manufacturing

Steve Damment

TITLE
Head of Research & Development
TENURE
1.1 yrs

David Benharris

TITLE
President of Midatech Pharma US Inc
AGE
53
TENURE
3.3 yrs
Board of Directors Tenure

Average tenure and age of the Midatech Pharma board of directors in years:

4.6
Average Tenure
55
Average Age
  • The tenure for the Midatech Pharma board of directors is about average.
Board of Directors

Rolf Stahel

TITLE
Non-Executive Chairman
COMPENSATION
£100K
AGE
74
TENURE
5.1 yrs

Nick Robbins-Cherry

TITLE
CFO, Company Secretary & Director
COMPENSATION
£188K
AGE
49
TENURE
4.6 yrs

Craig Cook

TITLE
CEO, COO & Director
AGE
51
TENURE
0.8 yrs

Simon de Vries

TITLE
Non-Executive Director
COMPENSATION
£36K
AGE
59
TENURE
14.5 yrs

Francesco Stellaci

TITLE
Chairman of Scientific Advisory Board

Simon Turton

TITLE
Senior Independent Non-Executive Director
COMPENSATION
£36K
AGE
50
TENURE
4.3 yrs

David Male

TITLE
Member of Scientific Advisory Board

Lorraine O'Driscoll

TITLE
Member of Scientific Advisory Board

Soledad Penades

TITLE
Member of Scientific Advisory Board

Dan McCurdy

TITLE
Member of Scientific Advisory Board
AGE
61
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Midatech Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Midatech Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

5MPB News

Simply Wall St News

5MPB Company Info

Description

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer. Midatech Pharma PLC is collaborating with universities and pharmaceutical companies to develop its platform technologies into a range of products. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.

Details
Name: Midatech Pharma Plc
5MPB
Exchange: DB
Founded: 2000
£37,770,474
403,399,613
Website: http://www.midatechpharma.com
Address: Midatech Pharma Plc
65 Innovation Drive,
Milton Park,
Abingdon,
Oxfordshire, OX14 4RQ,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM MTPH Ordinary Shares London Stock Exchange AIM Market GB GBP 08. Dec 2014
DB 5MPB Ordinary Shares Deutsche Boerse AG DE EUR 08. Dec 2014
NasdaqCM MTP SPONSORED ADR Nasdaq Capital Market US USD 08. Dec 2015
BST 5MPC SPONSORED ADR Boerse-Stuttgart DE EUR 08. Dec 2015
Number of employees
Current staff
Staff numbers
70
Midatech Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 21:59
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/02/27
Last earnings filing: 2018/09/27
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.